Xanthophyll eye protection composition and application thereof

Abstract

The invention discloses a xanthophyll eye-protecting composition and application thereof, and belongs to the field of traditional Chinese medicine technology and food. The eye protection composition is prepared from the following raw materials in parts by weight: 1 to 50 parts of lutein or lutein ester, 1 to 10 parts of zeaxanthin, 1 to 650 parts of anthocyanin, 1 to 5 parts of docosahexaenoic acid, 1 to 40 parts of radix puerariae, 1 to 40 parts of fructus lycii peptide, 1 to 10 parts of vitamin C and 1 to 15 parts of flos inulae nervosae. According to the composition, the raw materials with the eye protection effect are compounded with the specific new food raw materials including the inula nervosa, the bead peptide powder and the chimonanthus salicifolius, blue light damage of human retinal pigment epithelial cells ARPE-19 and inflammatory response caused by the blue light damage can be effectively relieved, and the composition can have the better eye protection effect.

Description

Technical Field

[0001] The invention belongs to the field of traditional Chinese medicine technology and food, and particularly relates to a lutein eye protection composition and application thereof. Background Art

[0002] Visual fatigue is a common health problem worldwide in the digital age. Prolonged exposure to high-energy, short-wavelength blue light emitted by electronic devices has been shown to be a major cause of visual fatigue. This short-wavelength light can penetrate the cornea and lens directly to the retina, triggering photochemical damage. This light damage activates the ocular immune system, leading to abnormally elevated levels of pro-inflammatory factors such as interleukin-6 and tumor necrosis factor-α, triggering a chronic inflammatory response. Over time, this increases the sensitivity of ocular surface nerve endings and reduces tear film stability, ultimately manifesting as typical visual fatigue symptoms such as dry eyes, soreness, photophobia, and blurred vision.

[0003] Epidemiology shows that 20%-30% of adolescents and 50%-80% of adults worldwide suffer from visual fatigue, and the situation is particularly serious in China.

[0004] Currently, the main methods for alleviating visual fatigue include artificial tears, behavioral interventions such as the "20-20-20 rule," optical correction and blue light-blocking glasses, low-concentration atropine medications, and physical therapy with warm compresses. Artificial tears can provide short-term relief for dry eyes, but the preservatives they contain can damage the cornea. The implementation rate of behavioral interventions is less than 30%. Optical correction lacks large-scale clinical validation and may affect color vision. Medication can cause side effects such as photophobia. Physical therapy with warm compresses has a short-lived effect and may aggravate meibomian gland problems. Summary of the Invention

[0005] The purpose of the present invention is to overcome at least one deficiency of the prior art and provide a lutein eye protection composition and its application.

[0006] The technical solution adopted in this application is:

[0007] The present application provides an eye protection composition, which comprises the following raw materials in parts by weight: 1-50 parts of lutein or lutein ester, 1-10 parts of zeaxanthin, 1-650 parts of anthocyanins, 1-5 parts of DHA (powder), 1-40 parts of kudzu root (powder) (PuerariaeLobatae Radix), 1-40 parts of wolfberry peptide, 1-10 parts of vitamin C (ascorbic acid), and 1-15 parts of Inulanervosa Wall.ex DC.

[0008] In some embodiments, the source of anthocyanins in the eye protection composition includes at least one of blueberry, Aronia melanocarpa (Michx.) Elliott (aronia), and other anthocyanin-containing plants.

[0009] In some embodiments, the eye protection composition comprises the following raw materials in parts by weight: 1-50 parts of lutein or lutein ester, 1-10 parts of zeaxanthin, 1-650 parts of anthocyanins, 1-5 parts of docosahexaenoic acid (DHA) powder, 1-40 parts of kudzu root powder, 1-40 parts of wolfberry peptide, 1-10 parts of vitamin C (ascorbic acid), 1-20 parts of pearl peptide powder, and 1-15 parts of Inula nervosa Wall.ex DC.

[0010] In some embodiments, the eye protection composition comprises the following raw materials in parts by weight: 10-50 parts of lutein or lutein ester, 2-10 parts of zeaxanthin, 100-650 parts of anthocyanins, 2-5 parts of DHA powder, 5-40 parts of kudzu root powder, 5-40 parts of wolfberry peptide, 2-10 parts of vitamin C (ascorbic acid), 4-20 parts of bead peptide powder, and 3-15 parts of Inula japonica flower.

[0011] In some embodiments, the eye protection composition comprises the following raw materials in parts by weight: 20-50 parts of lutein or lutein ester, 4-10 parts of zeaxanthin, 250-650 parts of anthocyanins, 3-5 parts of DHA powder, 10-40 parts of kudzu root powder, 10-40 parts of wolfberry peptide, 5-10 parts of vitamin C (ascorbic acid), 10-20 parts of bead peptide powder, and 7-15 parts of Inula japonica flower.

[0012] In some embodiments, the eye protection composition further comprises the following raw materials in parts by weight: 1-50 parts of Chimonanthus salicifolius HHHu.

[0013] In some embodiments, the eye protection composition further comprises the following raw materials in parts by weight: 5-50 parts of Chimonanthus chinensis.

[0014] In some embodiments, the ratio of the total weight of (i) lutein or lutein ester and zeaxanthin, (ii) anthocyanins, (iii) the total weight of kudzu root powder and wolfberry peptide, and (iv) the total weight of zhu peptide powder + scutellaria baicalensis + osmanthus fragrans is (15-60): (100-650): (10-80): (10-80), preferably (25-50): (250-550): (20-60): (30-70).

[0015] The present application provides the use of the eye protection composition as described in any one of the above items in the preparation of a product for protecting eyesight.

[0016] In some embodiments, the product comprises a medicine, a food, a health product, or a dietary supplement.

[0017] The present application also provides an eye protection composition, which comprises an active ingredient and food and pharmaceutically acceptable excipients; the active ingredient comprises the eye protection composition as described in any one of the above items.

[0018] In some embodiments, the food and pharmaceutically acceptable excipients include at least one of a sweetener, a sour agent, an anticaking agent, and a glidant.

[0019] In some embodiments, the sweetener comprises isomaltooligosaccharide; and / or the acidulant comprises citric acid; and / or the anticaking agent comprises magnesium stearate; and / or the glidant comprises silicon dioxide.

[0020] In some embodiments, the product comprises the following components: the eye protection composition, 0.01 to 1 part of the sweetener, 0.01 to 1 part of the sour agent, 0.01 to 1 part of the anti-caking agent, and 0.01 to 1 part of the glidant.

[0021] In some embodiments, the dosage form of the product includes tablets, capsules, granules, powders, solutions, powders, pills, emulsions or suspensions.

[0022] The beneficial effects of this application are:

[0023] The present application can effectively reduce blue light damage to human retinal pigment epithelial cells ARPE-19 and the inflammatory response caused thereby by compounding raw materials with eye protection effects with specific new food raw materials, including Inula japonica chinensis, pearl peptide powder and Chimonanthus chinensis. This can make the composition have better eye protection effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is a picture of the whole plant of Inula viridis. DETAILED DESCRIPTION

[0025] The preferred embodiments of the present invention will be described in detail below with reference to specific embodiments. It should be noted that the following specific embodiments are provided for illustrative purposes only and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.

[0026] Unless otherwise specified, the experimental methods used in the following specific examples are all conventional methods. Unless otherwise specified, the materials, reagents, etc. used in the following specific examples can be obtained from conventional commercial channels or prepared according to conventional methods in the art.

[0027] The present application can effectively reduce blue light damage to human retinal pigment epithelial cells ARPE-19 and the inflammatory response caused thereby by compounding raw materials with eye protection effects with specific new food raw materials, including Inula japonica chinensis, pearl peptide powder and Chimonanthus chinensis. This can make the composition have better eye protection effect.

[0028] The present application provides an eye protection composition, which comprises the following raw materials in parts by weight: 1-50 parts of lutein or lutein ester, 1-10 parts of zeaxanthin, 1-650 parts of anthocyanins, 1-5 parts of DHA powder, 1-40 parts of kudzu root powder, 1-40 parts of wolfberry peptide, 1-10 parts of vitamin C (ascorbic acid), and 1-15 parts of Inula japonica (small black medicine).

[0029] Inula nervosa Wall.ex DC., also known as the small black medicine, is a perennial herbaceous plant of the genus Inula in the Asteraceae family. It is mainly distributed in southwest China (such as Yunnan, Sichuan, Guizhou, etc.) and countries surrounding the Himalayas (such as Nepal and India). Figure 1 .

[0030] The "Hyperveined Inula" plant, mentioned in the Compendium of Materia Medica, has an upright stem, approximately 30 to 60 cm tall, and is densely covered with white hairs. Its leaves are alternate, oblong to lanceolate, with finely serrated edges. They are dark green on the outside and off-white on the underside. The veins are prominent and arranged in a network pattern, hence the name "Hyperveined." The inflorescence is terminal, approximately 2 to 3 cm in diameter, with yellow ligulate flowers and tubular flowers clustered in the center. Flowering occurs around the turn of summer and autumn, followed by fruiting. The achenes are cylindrical, with a white pappus at the tip, facilitating wind dispersal.

[0031] In some embodiments, the Inula serrata flower is a water extract or an alcohol extract of the Inula serrata flower, without limiting the extraction agent; the raw materials of the extract include the whole herb of the Inula serrata flower, or one or more of the roots, stems or flowers of the Inula serrata flower.

[0032] Inula japonica (small black medicine): has good anti-inflammatory effects and can improve eye inflammation.

[0033] Lutein or lutein esters: Lutein is the most important pigment in the macula of the retina, playing a crucial protective role. Lutein also has antioxidant and free radical properties, absorbing harmful light and protecting our visual cells from damage. Lutein esters break down into free lutein in the body, which replenishes the density of macular pigment in the macula and promotes its development.

[0034] Zeaxanthin: Zeaxanthin can selectively deposit at high levels in the macular area of ​​the retina of the eye, maintaining the normal and intact structure of the macular pigment, which can maintain healthy visual function and reduce the risk of age-related eye diseases.

[0035] Anthocyanins: scavenge free radicals and help slow down eye aging.

[0036] Docosahexaenoic Acid (DHA) Powder: DHA is the most abundant polyunsaturated fatty acid in the retina and is crucial to its structure and function. It also nourishes retinal nerve cells and, to a certain extent, relieves visual fatigue.

[0037] Kudzu root (Puerariae Lobatae Radix) powder: Contains compounds such as flavonoids and puerarin, which have antioxidant and anti-inflammatory properties.

[0038] Lycium barbarum peptides are bioactive peptides extracted from wolfberries (Lycium barbarum or Lycium chinense). They are typically obtained through enzymatic hydrolysis or fermentation of wolfberry protein and have potential antioxidant, immunomodulatory, and anti-fatigue benefits. Lycium barbarum peptides have a molecular weight range of 200-5000 Da, preferably 200-1000 Da.

[0039] In some embodiments, the source of anthocyanins in the eye protection composition includes blueberry, Aronia melanocarpa (Michx.) Elliott, and other anthocyanin-containing plants.

[0040] In some embodiments, the eye protection composition comprises the following raw materials in parts by weight: 1-50 parts of lutein or lutein ester, 1-10 parts of zeaxanthin, 1-650 parts of anthocyanins, 1-5 parts of docosahexaenoic acid (DHA) powder, 1-40 parts of kudzu root powder, 1-40 parts of wolfberry peptide, 1-10 parts of vitamin C (ascorbic acid), 1-20 parts of bead peptide powder, and 1-15 parts of Inula nervosa Wall.ex DC.

[0041] In some embodiments, the eye protection composition comprises the following raw materials in parts by weight: 10-50 parts of lutein or lutein ester, 2-10 parts of zeaxanthin, 100-650 parts of anthocyanins, 2-5 parts of docosahexaenoic acid (DHA), 5-40 parts of kudzu root, 5-40 parts of wolfberry peptide, 2-10 parts of vitamin C (ascorbic acid), 4-20 parts of bead peptide powder, and 3-15 parts of Inula japonica flower.

[0042] In some preferred embodiments, the eye protection composition comprises the following raw materials in parts by weight: 20-50 parts of lutein or lutein ester, 4-10 parts of zeaxanthin, 250-650 parts of anthocyanins, 3-5 parts of docosahexaenoic acid (DHA), 10-40 parts of kudzu root, 10-40 parts of wolfberry peptide, 5-10 parts of vitamin C (ascorbic acid), 10-20 parts of pearl peptide powder, and 7-15 parts of Inula japonica flower.

[0043] Globin Peptide: Globin Peptide is a mixture of oligopeptides derived from the red blood cells of quarantined pigs, using Aspergillus niger protease to hydrolyze pig hemoglobin. Globin Peptide improves oxygen supply and delivers nutrients to the eyes, nourishing them. In 2008, Globin Peptide was listed as a new food ingredient. The quality requirements for Globin Peptide are as follows:

[0044] Appearance: white or light yellow powder;

[0045] Protein content: ≥85.0%;

[0046] The proportion of relative molecular mass 100-1500: ≥85.0%;

[0047] Valine-valine-tyrosine-proline VVYP content: ≥0.5%;

[0048] Crude fat: ≤1.0%;

[0049] Carbohydrates: ≤10.0%;

[0050] Moisture: ≤5.0%;

[0051] Ash content: ≤6.0%;

[0052] The bead peptide powder used in this application is a bead peptide powder product that meets national quality requirements.

[0053] In some embodiments, the eye protection composition further comprises the following raw materials in parts by weight: 1-50 parts of Chimonanthus chinensis.

[0054] In some embodiments, the eye protection composition further comprises the following raw materials in parts by weight: 5-50 parts of Chimonanthus chinensis.

[0055] In some embodiments, the eye protection composition comprises the following raw materials in parts by weight: 1-50 parts of lutein or lutein ester, 1-10 parts of zeaxanthin, 1-650 parts of anthocyanins, 1-5 parts of DHA powder, 1-40 parts of kudzu root powder, 1-40 parts of wolfberry peptide, 1-10 parts of vitamin C (ascorbic acid), 1-20 parts of pearl peptide powder, 1-15 parts of Inula japonica (small black medicine), and 1-50 parts of Chimonanthus chinensis.

[0056] Chimonanthus salicifolius HHHu can relieve depression, regulate qi and invigorate the spleen, activate blood circulation and detoxify, and has a certain effect on eye care when combined with other raw materials in the eye protection composition.

[0057] After research, the present application found that by further adding an appropriate amount of Chimonanthus willowii to the above raw materials to form a composition, the components produced an unexpected synergistic effect, which can further improve the effect of the composition in relieving visual fatigue and protecting eyesight.

[0058] In some embodiments, the Chimonanthus chinensis is a water extract or an alcohol extract of Chimonanthus chinensis, without limiting the extraction reagent; the raw materials of the extract include one or more of the stems and leaves of Chimonanthus chinensis.

[0059] Furthermore, the ratio of the total weight of (i) lutein or lutein ester and zeaxanthin, (ii) anthocyanin, (iii) the total weight of kudzu root powder and wolfberry peptide, and (iv) the total weight of zhu peptide powder + scutellaria baicalensis (small black medicine) + osmanthus fragrans in the eye protection composition has a significant effect on the eye protection effect of the composition. When the ratio is (15-60): (100-650): (10-80): (10-80), the composition can have a better eye protection effect. The ratio is preferably (25-50): (250-550): (20-60): (30-70).

[0060] The present application further provides a method for preparing the eye protection composition, comprising the step of mixing the components.

[0061] In some embodiments, the method for preparing the eye protection composition comprises the following steps:

[0062] S1: Weigh the raw materials according to the weight ratio;

[0063] S2: Add the weighed raw materials into the mixing equipment and stir thoroughly for 25-30 minutes;

[0064] S3: Pack the evenly mixed materials into quantitative packages.

[0065] The eye protection composition described herein can be combined with relevant edible excipients through conventional production processes to produce products, including medicines and foods, that relieve visual fatigue and protect vision. These products are safe, effective, and have a pleasant taste for a wide range of consumers, demonstrating promising development and application prospects.

[0066] The present application provides the use of the eye protection composition in preparing products for protecting vision.

[0067] In some embodiments, the product includes a medicine, a food, a health product, or a dietary supplement.

[0068] The present application provides a product for protecting eyesight, which comprises an active ingredient and a food or pharmaceutically acceptable excipient; the active ingredient comprises the eye protection composition as described above.

[0069] In some embodiments, the food and pharmaceutically acceptable excipients include at least one of a sweetener, a sour agent, an anticaking agent, and a glidant.

[0070] In some embodiments, the sweetener comprises isomaltooligosaccharide; and / or the acidulant comprises citric acid; and / or the anticaking agent comprises magnesium stearate; and / or the glidant comprises silicon dioxide.

[0071] In some embodiments, the product comprises the following components: the eye protection composition, 0.01 to 1 part of the sweetener, 0.01 to 1 part of the sour agent, 0.01 to 1 part of the anti-caking agent, and 0.01 to 1 part of the glidant.

[0072] In some embodiments, the dosage form of the product includes tablets, capsules, granules, powders, solutions, granules, pills, emulsions or suspensions.

[0073] The present application will be further described below with reference to the embodiments.

[0074] Example 1

[0075] This embodiment provides an eye protection composition, which includes the following raw materials in parts by weight: 30 parts of lutein / lutein ester, 5 parts of zeaxanthin, 370 parts of anthocyanins, 3 parts of DHA powder, 20 parts of kudzu root powder, 15 parts of wolfberry peptide, 5 parts of vitamin C, and 15 parts of Inula japonica (small black medicine).

[0076] The preparation method of the eye protection composition comprises the following steps:

[0077] S1: Weigh the above raw materials according to the weight ratio.

[0078] S2: Put the weighed materials into the mixing equipment and stir them thoroughly for 30 minutes to ensure uniform mixing.

[0079] S3: Use an automatic filling machine to quantitatively package the evenly mixed materials to obtain the finished product.

[0080] Example 2

[0081] This embodiment provides an eye protection composition, which includes the following raw materials in parts by weight: 40 parts of lutein / lutein ester, 8 parts of zeaxanthin, 570 parts of anthocyanins, 5 parts of DHA powder, 30 parts of kudzu root powder, 30 parts of wolfberry peptide, 8 parts of vitamin C, and 15 parts of Inula japonica (small black medicine).

[0082] The preparation method of the eye protection composition is the same as that of Example 1.

[0083] Example 3

[0084] This embodiment provides an eye protection composition, which includes the following raw materials in parts by weight: 20 parts of lutein / lutein ester, 5 parts of zeaxanthin, 265 parts of anthocyanins, 4 parts of DHA powder, 10 parts of kudzu root powder, 10 parts of wolfberry peptide, 6 parts of vitamin C, and 15 parts of Inula japonica (small black medicine).

[0085] The preparation method of the eye protection composition is the same as that of Example 1.

[0086] Example 4

[0087] This embodiment provides an eye protection composition, which includes the following raw materials in parts by weight: 30 parts of lutein / lutein ester, 5 parts of zeaxanthin, 350 parts of anthocyanins, 3 parts of DHA powder, 20 parts of kudzu root powder, 15 parts of wolfberry peptide, 5 parts of vitamin C, 20 parts of bead peptide powder, and 15 parts of Inula japonica (small black medicine).

[0088] The preparation method of the eye protection composition is the same as that of Example 1.

[0089] Example 5

[0090] This embodiment provides an eye protection composition, which includes the following raw materials in parts by weight: 40 parts of lutein / lutein ester, 8 parts of zeaxanthin, 550 parts of anthocyanins, 5 parts of DHA powder, 30 parts of kudzu root powder, 30 parts of wolfberry peptide, 8 parts of vitamin C, 20 parts of bead peptide powder, and 15 parts of Inula japonica (small black medicine).

[0091] The preparation method of the eye protection composition is the same as that of Example 1.

[0092] Example 6

[0093] This embodiment provides an eye protection composition, which includes the following raw materials in parts by weight: 20 parts of lutein / lutein ester, 5 parts of zeaxanthin, 250 parts of anthocyanins, 4 parts of DHA powder, 10 parts of kudzu root powder, 10 parts of wolfberry peptide, 6 parts of vitamin C, 15 parts of bead peptide powder, and 15 parts of Inula japonica (small black medicine).

[0094] The preparation method of the eye protection composition is the same as that of Example 1.

[0095] Example 7

[0096] This embodiment provides an eye protection composition, which includes the following raw materials in parts by weight: 30 parts of lutein / lutein ester, 5 parts of zeaxanthin, 350 parts of anthocyanins, 3 parts of DHA powder, 20 parts of kudzu root powder, 15 parts of wolfberry peptide, 5 parts of vitamin C, 15 parts of bead peptide powder, 10 parts of Inula japonica (small black medicine), and 10 parts of Chimonanthus chinensis.

[0097] The preparation method of the eye protection composition is the same as that of Example 1.

[0098] Example 8

[0099] This embodiment provides an eye protection composition, which includes the following raw materials in parts by weight: 40 parts of lutein / lutein ester, 8 parts of zeaxanthin, 550 parts of anthocyanins, 5 parts of DHA powder, 30 parts of kudzu root powder, 30 parts of wolfberry peptide, 8 parts of vitamin C, 10 parts of bead peptide powder, 8 parts of Inula japonica (small black medicine), and 17 parts of Chimonanthus chinensis.

[0100] The preparation method of the eye protection composition is the same as that of Example 1.

[0101] Example 9

[0102] This embodiment provides an eye protection composition, which includes the following raw materials in parts by weight: 20 parts of lutein / lutein ester, 5 parts of zeaxanthin, 250 parts of anthocyanins, 4 parts of DHA powder, 10 parts of kudzu root powder, 10 parts of wolfberry peptide, 6 parts of vitamin C, 10 parts of bead peptide powder, 10 parts of Inula japonica (small black medicine), and 10 parts of Chimonanthus chinensis.

[0103] The preparation method of the eye protection composition is the same as that of Example 1.

[0104] Example 10

[0105] This embodiment provides an eye protection composition, which includes the following raw materials in parts by weight: 30 parts of lutein / lutein ester, 5 parts of zeaxanthin, 350 parts of anthocyanins, 3 parts of DHA powder, 20 parts of kudzu root powder, 15 parts of wolfberry peptide, 5 parts of vitamin C, 15 parts of bead peptide powder, 10 parts of Inula japonica (small black medicine), and 30 parts of Chimonanthus chinensis.

[0106] The preparation method of the eye protection composition is the same as that of Example 1.

[0107] Example 11

[0108] This embodiment provides an eye protection preparation, which includes the following raw materials in parts by weight: 30 parts of lutein / lutein ester, 5 parts of zeaxanthin, 350 parts of anthocyanins, 3 parts of DHA powder, 20 parts of kudzu root powder, 15 parts of wolfberry peptide, 5 parts of vitamin C, 15 parts of bead peptide powder, 10 parts of Inula japonica (small black medicine), 10 parts of Chimonanthus willowii, 0.1 part of steviol glycosides, 0.08 part of citric acid, 0.6 part of magnesium stearate, and 0.4 part of silicon dioxide.

[0109] The preparation method of the preparation comprises the following steps:

[0110] S1: Weigh the above raw materials according to the weight ratio.

[0111] S2: Put the weighed materials into the mixing equipment and stir them thoroughly for 30 minutes to ensure uniform mixing.

[0112] S3: Use an automatic filling machine to quantitatively package the evenly mixed materials to obtain the finished product.

[0113] Comparative Example 1

[0114] This comparative example provides an eye protection component, which includes the following raw materials in parts by weight: 15 parts of Inula japonica (small black medicine).

[0115] The preparation method is the same as that in Example 1.

[0116] Comparative Example 2

[0117] This comparative example provides an eye protection component, which includes the following raw materials in parts by weight: 20 parts of bead peptide powder.

[0118] The preparation method is the same as that in Example 1.

[0119] Comparative Example 3

[0120] This comparative example provides an eye protection composition, which comprises the following raw materials in parts by weight: 20 parts of zhupeptide powder and 15 parts of Xianmai Inula flower (small black medicine).

[0121] The preparation method of the composition is the same as that of Example 1.

[0122] Comparative Example 4

[0123] This comparative example provides an eye protection component, which includes the following raw materials in parts by weight: 10 parts of Chimonanthus chinensis.

[0124] The preparation method is the same as that in Example 1.

[0125] Comparative Example 5

[0126] This comparative example provides an eye protection composition, which includes the following raw materials in parts by weight: 30 parts of lutein / lutein ester, 5 parts of zeaxanthin, 350 parts of anthocyanins, 3 parts of DHA powder, 20 parts of kudzu root powder, 15 parts of wolfberry peptide, and 5 parts of vitamin C.

[0127] The preparation method of the composition is the same as that of Example 1.

[0128] Comparative Example 6

[0129] This comparative example provides an eye protection composition, which includes the following raw materials in parts by weight: 5 parts of lutein / lutein ester, 1 part of zeaxanthin, 120 parts of anthocyanins, 1 part of DHA powder, 4 parts of kudzu root powder, 4 parts of wolfberry peptide, 1 part of vitamin C, 1 part of bead peptide powder, 5 parts of Inula japonica (small black medicine), and 2 parts of Chimonanthus chinensis.

[0130] The preparation method of the composition is the same as that of Example 1.

[0131] Comparative Example 7

[0132] This comparative example provides an eye protection composition, which includes the following raw materials in parts by weight: 60 parts of lutein / lutein ester, 12 parts of zeaxanthin, 660 parts of anthocyanins, 5 parts of DHA powder, 70 parts of kudzu root powder, 70 parts of wolfberry peptide, 5 parts of vitamin C, 35 parts of bead peptide powder, 40 parts of Inula japonica (small black medicine), and 75 parts of Chimonanthus chinensis.

[0133] The preparation method of the composition is the same as that of Example 1.

[0134] Test example: Cell efficacy verification test

[0135] This test example tests the effects of the compositions / eye-protecting ingredients prepared in Examples 1-10 and Comparative Examples 1-7.

[0136] Cells were cultured in complete medium (basal medium was DMEM high-glucose medium supplemented with 10% FBS and 1% antibiotics). DMEM high-glucose medium was purchased from Beijing Solebold Technology Co., Ltd., and fetal bovine serum (FBS) was purchased from Zhejiang Tianhang Biotechnology Co., Ltd. CCK8 reagent was purchased from Beijing Solebold Technology Co., Ltd. Interleukin-6 (IL-6) and tumor necrosis factor (TNF-α) kits were purchased from Thermo Fisher Scientific (China) Co., Ltd. Nitric oxide (NO) detection reagent was purchased from Shanghai MacLean Biochemical Technology Co., Ltd.

[0137] 1. Effects on cell viability

[0138] The test cells were human retinal pigment epithelial cells (ARPE-19). ARPE-19 cells (human retinal pigment epithelial cell line) were irradiated with blue light and cell activity was detected by CCK-8 assay to evaluate the toxic effects of blue light on retinal cells and the intervention effect of the composition of the embodiment. The specific steps of the cell experiment are as follows:

[0139] ARPE-19 cells were seeded in 96-well plates with 100 μL complete medium per well and 5 × 10 3 Cells were incubated at 37°C and 5% CO 2 After culturing overnight in a cell culture incubator, the old complete medium was discarded, and fresh complete medium was added to the blank group and the model group. Separately, the products of Examples 1-10 and Comparative Examples 1-7 of equal weight were weighed, first dissolved with DMSO to prepare a 20 mg / mL stock solution, and then diluted with fresh complete medium to obtain the corresponding product solution (concentration of 50 ug / mL). 100 uL of the corresponding product solution was added to each treatment group, and the cells were cultured in a 37°C, 5% CO2 cell culture incubator for 24 h. The old complete medium (or product solution) was discarded, the cells were washed twice with PBS, and fresh complete medium was added. ARPE-19 cells (except the blank group) were irradiated under blue light with an illumination intensity of 4000-5333 Lux for 2 h, 10 uL of CCK8 was added to each well, and after incubation for 1 h, the OD value was detected at a wavelength of 450 nm on a microplate reader.

[0140] Table 1 shows the results of the effects of each treatment group on the cell viability of human retinal pigment epithelial cells ARPE-19.

[0141] Table 1

[0142] Group Cell survival rate (%) Blank group 100.33±2.38a Model Group 53.22±1.98f Example 1 88.93±2.43c Example 2 89.03±2.20c Example 3 88.79±2.10c Example 4 93.26±2.95b Example 5 93.13±2.46b Example 6 93.46±2.42b Example 7 98.70±1.24a Example 8 99.06±2.18a Example 9 98.24±2.71a Example 10 99.41±2.42a Comparative Example 1 54.21±2.43f Comparative Example 2 53.81±2.45f Comparative Example 3 54.36±2.60f Comparative Example 4 53.69±2.71f Comparative Example 5 77.93±2.02d Comparative Example 6 71.28±2.55e Comparative Example 7 78.33±1.65d

[0143] Different letters (a, b, c, d, e, f) in Table 1 indicate that there are significant statistical differences in the data between the groups (P < 0.05).

[0144] As shown in Table 1, compared with the blank group, the cell survival rate in the model group (blue light irradiation) was significantly reduced. Compared with the model group, the cell survival rate in the treatment groups of each embodiment was significantly improved.

[0145] Among them, the composition of Comparative Example 1, which contained only Inula oblongata, Comparative Example 2, which contained only zhu peptide powder, Comparative Example 3, which contained only zhu peptide powder and Inula oblongata, and Comparative Example 4, which contained only Chimonanthus chinensis, showed similar cell survival rates under blue light irradiation to that of the model group. This indicates that these components, when used alone, did not effectively reduce blue light damage to human retinal pigment epithelial (ARPE)-19 cells.

[0146] The composition of Comparative Example 5 is a basic component comprising lutein / lutein ester, zeaxanthin, anthocyanidins, DHA, kudzu root powder, wolfberry peptides, and vitamin C. These components contain many eye-protecting active ingredients that have been widely verified in the prior art, such as zeaxanthin and anthocyanidins, and have a clear blue light protection effect. The experimental results show that the cell survival rate of Comparative Example 5 under blue light irradiation is significantly increased by 46.4% compared with the model group. However, Example 1 adds Inula japonica to the ingredients of Comparative Example 5. The results show that the cell survival rate of the Example 1 treatment group is higher, which is 67.1% higher than that of the model group. Example 4 further adds pearl peptide powder to the ingredients of Example 1. The results show that the cell survival rate of the Example 4 treatment group is further improved, which is 75.2% higher than that of the model group. This shows that the specific proportions of raw materials produce a better synergistic effect, which can more effectively reduce the blue light damage of human retinal pigment epithelial cells ARPE-19.

[0147] Compared with Example 4, the composition of Example 7 further added Chimonanthus willowii, and the survival rate of the cells was improved after treatment with the composition, indicating that the composition formed by adding an appropriate amount of Chimonanthus willowii to the composition of Example 4 can further reduce blue light damage to human retinal pigment epithelial cells ARPE-19.

[0148] The compositions of Comparative Examples 6 and 7 used the same raw materials as the compositions of Examples 7-10. However, because the weight ratios of the raw materials in the compositions of Comparative Examples 6 and 7 were lower than the specified ratios, the compositions of Comparative Examples 6 and 7 showed lower survival rates in human retinal pigment epithelial (ARPE) cells compared to the compositions of Examples 7-10. This indicates that the compositions of Examples 7-10 are more effective in protecting human retinal pigment epithelial (ARPE) cells from blue light damage.

[0149] 2. Assessment of anti-inflammatory capacity at the cellular level

[0150] The test cells are human retinal pigment epithelial cells ARPE-19. The cell experiments are as follows:

[0151] ARPE-19 cells in the logarithmic growth phase were obtained, digested with trypsin, and counted. The cell density was adjusted to 2.5 × 10 5 cells / mL, 2 mL was inoculated into each well of a 6-well plate, i.e. 5×10 5The cells were cultured overnight in a 37°C, 5% CO2 cell culture incubator. After discarding the old complete medium, fresh complete medium was added to the blank and model groups. Separately, equal weights of the products of Examples 1-10 and Comparative Examples 1-7 were weighed, dissolved in DMSO to prepare a 20 mg / mL stock solution, and then diluted with fresh complete medium to obtain the corresponding product solution (concentration of 50 μg / mL). 2 mL of the corresponding product solution was added to each treatment group. After 24 hours of culture in a 37°C, 5% CO2 cell culture incubator, the old complete medium (or product solution) was discarded, the cells were washed twice with PBS, and fresh complete medium was added. ARPE-19 cells (except the blank group) were irradiated under blue light with an intensity of 4000-5333 Lux for 2 hours. The supernatant was then collected and the levels of nitric oxide (NO), interleukin-6 (IL-6), and tumor necrosis factor (TNF-α) were determined according to the kit instructions. The test results are shown in Table 2.

[0152] Table 2

[0153] Group NO concentration (uM) IL-6 concentration (pg / mL) TNF-α concentration (pg / mL) Blank group 9.86±0.62a 15.77±1.09a 26.34±1.95a Model Group 40.49±0.58f 44.89±1.14f 64.93±1.50f Example 1 20.00±0.87c 26.30±1.49c 36.92±1.63c Example 2 19.77±0.68c 25.80±1.89c 36.62±1.58c Example 3 20.06±0.75c 26.63±1.55c 37.05±1.31c Example 4 15.42±0.95b 22.30±1.99b 32.58±1.38b Example 5 15.36±0.73b 21.93±1.09b 31.95±1.06b Example 6 15.52±0.70b 22.47±1.83b 32.58±1.38b Example 7 10.44±0.33a 18.06±0.94a 28.07±1.48a Example 8 10.05±0.94a 17.63±1.30a 27.54±1.42a Example 9 10.68±0.62a 18.40±1.53a 28.50±1.76a Example 10 10.13±0.42a 17.76±0.80a 27.67±1.39a Comparative Example 1 40.26±0.72f 44.32±1.78f 64.31±1.94f Comparative Example 2 40.17±0.70f 44.46±1.47f 64.07±2.22f Comparative Example 3 39.97±0.51f 43.99±1.53f 63.74±1.82f Comparative Example 4 40.09±0.42f 44.51±1.53f 64.16±1.57f Comparative Example 5 26.23±0.98d 30.52±1.61d 41.58±1.73d Comparative Example 6 30.17±0.15e 35.43±1.90e 47.64±1.68e Comparative Example 7 25.98±0.82d 29.99±1.41d 40.99±1.49d

[0154] Different letters (a, b, c, d, e, f) in Table 2 indicate that there are significant statistical differences in the data between the groups (P < 0.05).

[0155] As shown in Table 2, compared with the blank group, the NO, IL-6 and TNF-α contents of ARPE-19 cells in the model group (blue light irradiation) were significantly increased, indicating that the blue light damaged cell model was successful.

[0156] Compared with the model group, the treatment groups of each example significantly reduced the levels of NO, IL-6 and TNF-α in ARPE-19 cells.

[0157] Among them, the composition of Comparative Example 1 contained only Inula oblongata, Comparative Example 2 contained only zhu peptide powder, Comparative Example 3 contained only zhu peptide powder and Inula oblongata, and Comparative Example 4 contained only Chimonanthus chinensis. The NO, IL-6, and TNF-α levels of ARPE-19 cells under blue light irradiation were similar to those of the model group. This indicates that these components, when used alone, did not show an effective ability to reduce the inflammatory response of human retinal pigment epithelial ARPE-19 cells under blue light irradiation.

[0158] The composition of Comparative Example 5 consists of a base composition of lutein / lutein esters, zeaxanthin, anthocyanins, DHA, kudzu root powder, wolfberry peptides, and vitamin C. These components contain a number of well-established eye-protecting active ingredients, such as zeaxanthin and anthocyanins, and demonstrate clear blue light protection. Experimental results showed that the levels of NO, IL-6, and TNF-α in ARPE-19 cells in the Comparative Example 5 treatment group significantly decreased when exposed to blue light compared to the model group.

[0159] However, Example 1 added Inula japonica on the basis of the ingredients of Comparative Example 5, and the results showed that the anti-inflammatory ability of the group treated with Example 1 was enhanced. Example 4 further added bead peptide powder to the components of Example 1, and the anti-inflammatory ability of the group treated with Example 4 was further enhanced. A better synergistic effect was produced between the raw materials, which can more effectively reduce the inflammatory response of human retinal pigment epithelial cells ARPE-19.

[0160] Compared with Example 4, the composition of Example 7 was added with Chimonanthus willowii, and the NO, IL-6 and TNF-α levels of the cells were further reduced after treatment with the composition, indicating that the composition formed by adding an appropriate amount of Chimonanthus willowii to the composition of Example 1 can further reduce the inflammatory response of human retinal pigment epithelial cells ARPE-19.

[0161] The compositions of Comparative Examples 6 and 7 share the same raw material types as the compositions of Examples 7-10. However, because the weight ratios of the raw materials in the compositions of Comparative Examples 6 and 7 are lower than the specified ratios, the compositions of Comparative Examples 6 and 7 are less effective than the compositions of Examples 7-10 in reducing cellular NO, IL-6, and TNF-α expression after blue light irradiation. This suggests that the compositions of Examples 7-10 are more effective in protecting human retinal pigment epithelial ARPE-19 cells from blue light damage.

[0162] The above results show that the eye protection composition of the present application can effectively protect human retinal pigment epithelial cells ARPE-19 from the inflammatory response caused by blue light damage, thereby relieving visual fatigue and protecting vision. The ingredients of the composition of the present invention complement each other, so that the eye protection composition can effectively relieve visual fatigue and protect vision in a long-term manner.

[0163] The technical features of the above-described embodiments can be combined arbitrarily. To make the description concise, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0164] The above-described embodiments merely illustrate several implementations of the present invention, and while their descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art would be able to make numerous variations and improvements without departing from the spirit of the present invention, all of which fall within the scope of protection of the present invention. Therefore, the scope of protection of the present invention shall be determined by the appended claims.

Claims

1. An eye protection composition, characterized in that The eye protection composition comprises the following raw materials in parts by weight: 1-50 parts of lutein or lutein ester, 1-10 parts of zeaxanthin, 1-650 parts of anthocyanins, 1-5 parts of docosahexaenoic acid (DHA), 1-40 parts of kudzu root, 1-40 parts of wolfberry peptide, 1-10 parts of vitamin C (ascorbic acid), and 1-15 parts of Inula nervosa Wall.ex DC.

2. The eye protection composition according to claim 1, characterized in that The anthocyanin source in the eye protection composition includes at least one of blueberry, Aronia melanocarpa (Michx.) Elliott, and other anthocyanin-containing plants.

3. The eye protection composition according to claim 1 or 2, characterized in that The eye protection composition comprises the following raw materials in parts by weight: 1-50 parts of lutein or lutein ester, 1-10 parts of zeaxanthin, 1-650 parts of anthocyanins, 1-5 parts of docosahexaenoic acid (DHA), 1-40 parts of kudzu root, 1-40 parts of wolfberry peptide, 1-10 parts of vitamin C (ascorbic acid), 1-20 parts of pearl peptide powder, and 1-15 parts of Inula nervosa Wall.ex DC.

4. The eye protection composition according to claim 1 or 2, characterized in that The eye protection composition comprises the following raw materials in parts by weight: 10-50 parts of lutein or lutein ester, 2-10 parts of zeaxanthin, 100-650 parts of anthocyanins, 2-5 parts of docosahexaenoic acid (DHA), 5-40 parts of kudzu root, 5-40 parts of wolfberry peptide, 2-10 parts of vitamin C (ascorbic acid), 4-20 parts of pearl peptide powder, and 3-15 parts of Inula japonica flower.

5. The eye protection composition according to claim 1 or 2, characterized in that The eye protection composition comprises the following raw materials in parts by weight: 20-50 parts of lutein or lutein ester, 4-10 parts of zeaxanthin, 250-650 parts of anthocyanins, 3-5 parts of docosahexaenoic acid (DHA), 10-40 parts of kudzu root, 10-40 parts of wolfberry peptide, 5-10 parts of vitamin C (ascorbic acid), 10-20 parts of pearl peptide powder, and 7-15 parts of Inula japonica flower.

6. The eye protection composition according to any one of claims 1 to 5, characterized in that The eye protection composition further comprises the following raw materials in parts by weight: 1-50 parts of Chimonanthus salicifolius HHHu, preferably 5-50 parts of Chimonanthus salicifolius HHHu.

7. The eye protection composition according to claim 6, characterized in that The ratio of the total weight parts of the lutein or lutein ester and zeaxanthin, the weight parts of anthocyanins, the total weight parts of kudzu root and wolfberry peptides, and the total weight parts of pearl peptide powder+inula japonica flower+chimonanthus chinensis is (15-60):(100-650):(10-80):(10-80), preferably (25-50):(250-550):(20-60):(30-70).

8. Use of the eye protection composition according to any one of claims 1 to 7 in the preparation of eye protection products.

9. The use according to claim 8, characterized in that The product includes at least one of medicine, food, health care product, and dietary supplement.

10. An eye protection composition, characterized in that: The product comprises an active ingredient and food and pharmaceutically acceptable excipients; the active ingredient comprises the eye protection composition according to any one of claims 1 to 7.

Images